MedTrace Logo

Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer

NCT01494012 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2017-04-28

No results posted yet for this study

Summary

This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy (SBRT) in treating patients with metastatic or recurrent ovarian cancer or primary peritoneal cancer. SBRT may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

Conditions

  • Recurrent Ovarian Epithelial Cancer
  • Recurrent Ovarian Germ Cell Tumor
  • Malignant Tumor of Peritoneum
  • Stage IV Ovarian Epithelial Cancer
  • Stage IV Ovarian Germ Cell Tumor

Interventions

RADIATION

stereotactic body radiation therapy

Undergo SBRT

PROCEDURE

positron emission tomography

Undergo FDG-PET/CT

PROCEDURE

computed tomography

Undergo FDG-PET/CT

OTHER

questionnaire administration

Ancillary studies

DRUG

fludeoxyglucose F 18

Undergo FDG-PET/CT

Sponsors & Collaborators

Principal Investigators

  • Elizabeth Kidd · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01494012 on ClinicalTrials.gov